Business Wire

AlgoTx Raises €20M to Conduct ATX01’s Phase 2 Program in Peripheral Neuropathic Pain


European biotech AlgoTx, the developer of first-in-class treatment ATX01 for chemotherapy-induced peripheral neuropathy (CIPN), announced today the success of a €20M Series B fundraising led by Relyens Innovation Santé / Turenne Capital , followed by UI Investissement, and historical investors Bpifrance through its Innobio 2 fund and Omnes Capital. Early and new business angel investors also significantly participated in this financing round, and AlgoTx secured an additional 1M€ in non-dilutive financing. The proceeds will be used to demonstrate the clinical efficacy of ATX01 in neuropathic pain.

Bervin Bouani, Investment Director at Turenne Capital, commented: “We are very proud to lead this strategic financing round to support AlgoTx to continue the clinical development of ATX01 lead candidate that has the potential to significantly improve the lives of patients with neuropathic pain. We look forward to working with Stéphane and his outstanding team to transform AlgoTx into a global pain player.”

Following the demonstration of ATX01’s early clinical safety and low systemic passage in Phase 1, the Phase 2 “ACT” study will now assess ATX01’s ability to reduce pain in adult CIPN patients – a program granted “fast-track” designation by FDA. In parallel, the Phase 2 “EASE” study will explore ATX01’s efficacy in the debilitating pain of erythromelalgia, a program for which ATX01 was granted “Orphan Disease Designation” in the US and Europe.

Stéphane Thiroloix, Founder & CEO of AlgoTx, says: “It is incredibly exciting to start the efficacy trials of ATX01, supported by such a high-profile syndicate of investors. We look forward to enrolling patients in our studies any day now.”

Over half of cancer patients treated with chemotherapy develop CIPN and experience sensory symptoms and pain in the hands and feet: loss of sensitivity, tingling, burning, cold and intense pain can persist for months to years after treatment. It affects over two million patients in the US and Europe and represents a leading cause for modification or interruption of chemotherapy. To this date, no therapeutic approach has offered a satisfactory response for patients and their caregivers, oncologists, neurologists and pain specialists.

« We are very pleased to support the AlgoTx team in the development of ATX01, driven by our belief in its significant impact in the treatment of CIPN and other neuropathic pain. AlgoTx can truly transform the lives of patients suffering from these conditions », says Pauline de Breteuil Senior Partner UI Investissement / FCPI Majycc Innovation Santé.

About AlgoTx
AlgoTx develops novel treatments for complex pain, with lead program ATX01 in Phase 2 in chemotherapy-induced peripheral neuropathy (NCT05593614) and erythromelalgia. More information at
ACT study : ATX01 for the pain of ChemoTherapy, (NCT05593614). EASE study : Efficacy of ATX01 / Study in Erythromelalgia.

Launched in 2014, Relyens Innovation Santé is is an evergreen venture capital vehicle specializing in health innovation controlled and owned by Relyens, a mutual insurance company specializing in the risk management of health, social and medical players. Relyens is the leading French player in medical civil liability. Advised by Turenne Santé (Health Division of Turenne Group), Relyens Innovation Santé's mission is to support the growth and development phases of innovative companies in the health sector.
Turenne Group, one of the leading private equity companies in France, has been supporting entrepreneurs for 23 years in their company’s innovation, development and transfer projects. As an independent player, the Group has assets of €1.4 billion under management. Its teams, made up of 68 professionals, including 52 investors, based in Paris, Lille (Nord Capital Partenaires), Lyon, Bordeaux, Marseille, Nice and Metz, support 290 business leaders, particularly in the healthcare, hospitality, innovation, BtoB services, and in the digital and impact sectors. With more than €300m, our healthcare team (Turenne Santé) invests across the entire value creation chain for healthcare companies through various investment approaches.
For more information: /

About Bpifrance and InnoBio 2
Bpifrance is the French national investment bank: it finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services (training, consultancy) to help entrepreneurs meet their challenges (innovation, export).
InnoBio 2 is an investment fund dedicated to life sciences, managed by Bpifrance, which is also one of the LPs alongside Sanofi, Boehringer Ingelheim, Takeda, Ipsen, Servier, BMS, European Investment Fund and Pasteur Mutualité. InnoBio 2, with €203 million, aims to invest in companies developing innovative products and services, close to or in early clinical development, with the objective of bringing them until the clinical proof of concept. InnoBio 2 takes minority equity stake in companies and can lead or co-lead the investment rounds.
For more information, please visit: – Follow us on Twitter : @bpifrance - @BpifrancePresse

About Omnes
Omnes is a leading Paris-based European investor in private equity and infrastructure. With more than €5 billion in assets under management, Omnes provides companies with the equity capital they need to grow through its four core businesses: Venture Capital, Buyout & Growth Capital, Infrastructure and Co-Investment. With more than 30 trade sales and nearly 15 IPOs in 20 years (including Themis Bioscience, Biovex, arGEN-X, Novaled and Direct Energie), Omnes Venture Capital team is a leading French player in financing innovative SMEs with dual expertise in the deep-tech and healthcare sectors. Omnes is committed to ESG issues and has set up the Omnes Foundation in aid of children’s charities. The company is also a signatory to the United Nations Principles for Responsible Investment (PRI).

About UI Investissement
UI Investissement is an independent, specialized company in the development of unlisted French companies with €1.5 billion under management. For over 50 years, UI Investissement has been committed to work alongside the managers of growing SMEs and STIs to help them emerge as economically and sustainably successful businesses through its focus on three areas: health, agro-business, and business services.
With its expertise, UI Investissement provides support to companies in the health sector at all stages of their development and plays a central role in the ecosystem. It is through the Majycc Innovation Santé fund that UI Investissement supports entrepreneurs who aim to be the architects of tomorrow's health. The roots of Majycc Innovation Santé are deeply connected to the DNA of several private clinic groups, nursing home groups, and mutual health insurance companies, representing entrepreneurship, health and human values, respect for corporate culture, and the projects of the individuals who build them.

To view this piece of content from, please give your consent at the top of this page.

Contact information

AlgoTx : Geneviève Cliquet Consultant : +33(0) 607 500 567
Turenne Capital : Sandra Capela : ; Agence TADEO, Louis Branger - 06 76 23 52 85
Bpifrance : Juliette Fontanillas :
Omnes Capital: Yanie de Nadaillac : - +33(0) 7 63 13 65 74
UI Investissement : Laurent Maillard

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Rimini Street Formally Launches Rimini ONE™, an End-to-End Outsourcing Solution for Enterprise Applications, Databases and Technology Software22.3.2023 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, products and services, the leading third-party support provider for Oracle and SAP software, and a Salesforce and AWS partner, today announced the formal launch of Rimini ONE™, its outsourcing service program designed to offer a comprehensive set of unified, integrated services to run, manage, support, customize, configure, connect, protect, monitor, and optimize enterprise applications, databases and technology software. This press release features multimedia. View the full release here: Rimini ONE’s comprehensive, trusted, and proven family of unified solutions optimize, evolve, and transform clients’ enterprise software and organization to support competitive advantage, profitability, and growth. (Graphic: Business Wire) “We developed Rimini ONE in response to clients requesting a fully outsourced solution for their enterprise sof

AGCO Agriculture Foundation Awards $50,000 Grant to Providence Farm Collective22.3.2023 16:00:00 EET | Press release

The AGCO Agriculture Foundation (AAF), a private foundation with the vision to prevent and relieve hunger through sustainable agricultural development, today announced a USD 50,000 grant to Providence Farm Collective (PFC) to support implementation of a holistic on-farm compost generation system and optimization of post-harvest efficiency and food safety at its 37-acre farm in Orchard Park, NY. This press release features multimedia. View the full release here: AGCO Agriculture Foundation Awards $50,000 Grant to Providence Farm Collective. Funds will support refugee and under-resourced communities to grow food and improve food handling and safety practices. (Graphic: Business Wire) PFC is a non-profit that supports refugee, immigrant, Black and low-income farmers in Western New York who cannot otherwise access farmland. The organization started in 2017 as a grassroots effort by the Somali Bantu community to return to their agric

Luno Announces Leadership Transition22.3.2023 13:00:00 EET | Press release

Luno, a leading cryptocurrency wallet and exchange serving customers across 40 countries, today announced a series of strategic initiatives to position the company for its next phase of growth. Luno’s co-founder and Chief Executive Officer Marcus Swanepoel is moving into a new role as Executive Chairman, and Chief Operating Officer James Lanigan, who has been with the company for five years, is elevated to CEO. As Executive Chairman, Swanepoel will continue to work closely with Lanigan to guide Luno’s vision and strategy, while focusing on broadening Luno’s investor base to support the company’s next stage of growth. As part of this process, Luno has hired Canaccord Genuity Group to help bring on new institutional and strategic investors alongside Digital Currency Group (DCG) to fund scaling, support expansion, accelerate market share gain, and prepare the company for an eventual public listing. “Co-founding and serving as the CEO of Luno for the past ten years has been the greatest ho

The LYCRA Company Announces Latest Higg Achievements22.3.2023 12:00:00 EET | Press release

The LYCRA Company, a global leader in developing innovative fiber and technology solutions for the apparel and personal care industries, announced today that several of its manufacturing sites had their Higg Facility Environmental Module (Higg FEM) and Higg Facility Social & Labor Module (Higg FSLM) self-assessments verified by an independent third party last year and achieved scores in the top quartile. This press release features multimedia. View the full release here: The LYCRA Company’s manufacturing sites in Waynesboro, Virginia; Maydown, Northern Ireland; and Foshan, China, completed verification for the Higg FEM module, while its Tuas, Singapore, and Maydown sites completed verification for the Higg FSLM module. The LYCRA Company’s manufacturing sites in Waynesboro, Virginia; Maydown, Northern Ireland; and Foshan, China, completed verification for the Higg FEM module, while its Tuas, Singapore, and Maydown sites completed

The European Circular Economy Project TREASoURcE to Install Stationary Battery Systems for Energy Storage Purposes at Two Demo Sites in Norway and Finland22.3.2023 11:44:00 EET | Press release

As part of the four-year circular economy project TREASoURcE, a stationary Battery Energy Storage System (BESS) built with used electric vehicle batteries will be commissioned at two demo sites in Norway and Finland over the summer 2023. The demonstrations aim to increase knowledge of the batteries’ second life and their functionality and how stationary batteries can be used to balance electricity demand. The intended result is to accelerate the market uptake of this technology. The selected demo sites are Rudskogen Motorsports Centre in Viken, Norway, and the municipally owned Lempäälä House in Lempäälä, Finland. The pilot is led by the Norwegian research organisation SINTEF and the battery systems will be supplied by the Norwegian company ECO STOR AS. The system stores excess energy from solar panels which in turn is used to cut power peaks for the facilities. The BESS can thus be used to shift energy consumption to reduce the energy cost and provide stabilization for the entire powe

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom